Sequester May Further Depress AmerisourceBergen’s Oncology Drug Sales
Wholesalers AmerisourceBergen and McKesson discuss the potential impact of the federal budget sequester and the resulting cut to Part B drug reimbursement on oncology drug sales.
You may also be interested in...
A 2% cut is being applied first to the average sales price for drugs reimbursed by Medicare Part B, and then another 2% is taken out of the 6% add-on. The approach compounds the overall reduction to a level that far exceeds the 2% Medicare cut required by sequestration, according to the groups.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.